Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 7/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29582023 | 0.82 | MAP1LC3B (0.70) | MAP1LC3BHTR2CADRA1AMEN1KMT2A | |
| SCHEMBL21821794 | 0.82 | MAP1LC3B (0.70) | MAP1LC3BHTR2CADRA1AMEN1KMT2A | |
| SCHEMBL1780428 | 0.79 | MAP1LC3B (0.69) | MAP1LC3BADRA1AMEN1KMT2AALDH1A1 | |
| SCHEMBL22056783 | 0.79 | MAP1LC3B (1.00) | MAP1LC3BHTR2CMEN1KMT2AALDH1A1 | |
| SCHEMBL21821762 | 0.77 | MAP1LC3B (0.62) | MAP1LC3BHTR2CMEN1KMT2APKM | |
| SCHEMBL29582438 | 0.77 | MAP1LC3B (0.62) | MAP1LC3BHTR2CMEN1KMT2APKM | |
| SCHEMBL21821649 | 0.77 | MAP1LC3B (0.66) | MAP1LC3BSLC6A2SLC6A4ALDH1A1MAPT | |
| SCHEMBL29581585 | 0.77 | MAP1LC3B (0.66) | MAP1LC3BSLC6A2SLC6A4ALDH1A1MAPT | |
| SCHEMBL1780317 | 0.75 | MAP1LC3B (1.00) | MAP1LC3BMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL21774003 | 0.74 | MAP1LC3B (0.70) | MAP1LC3BMEN1KMT2AUSP2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11529321-B2 | Use of aminomethylenecyclohexane-1,3-dione compound | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-12-20 | — | — | US | disclosed |
| US-20200170966-A1 | USE OF AMINOMETHYLENECYCLOHEXANE-1,3-DIONE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-06-04 | — | — | US | disclosed |
| US-8592430-B2 | Quinazolin-oxime derivatives as Hsp90 inhibitors | DAC SLR (IT) | 2013-11-26 | — | — | US | disclosed |
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | disclosed |
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| EP-2144889-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC S.r.l. (IT) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008142720-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008142720-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | MAP1LC3B 726/4885HTR2C 2746/4885ADRA1A 1689/4885 |
| US-20200170966-A1 | USE OF AMINOMETHYLENECYCLOHEXANE-1,3-DIONE COMPOUND | ATG7, BECN1, SQSTM1 | MAP1LC3B 10/4885HTR2C 1192/4885ADRA1A 2172/4885 |
| US-11529321-B2 | Use of aminomethylenecyclohexane-1,3-dione compound | ATG7, BECN1, SQSTM1 | MAP1LC3B 10/4885HTR2C 1192/4885ADRA1A 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.